Chongqing Taiji Industry(Group) (600129) Fundamentals 2026 — P/E 77.0x, Revenue Analysis | SniperIQ
Chongqing Taiji Industry(Group) (600129) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥8.8B, trading at ¥15.94 on the SHH. This SniperIQ fundamentals page covers Chongqing Taiji Industry(Group)'s valuation (P/E 77.0x, P/B 2.5x), profitability (net margin 1.1%), revenue (¥10.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Chongqing Taiji Industry(Group)'s market cap?
Chongqing Taiji Industry(Group) (600129) has a market capitalization of approximately ¥8.8B, trading at ¥15.94 on the SHH. Market cap moves with the live share price.
What is Chongqing Taiji Industry(Group)'s P/E ratio?
Chongqing Taiji Industry(Group)'s trailing twelve-month P/E ratio is 77.0x, with a price-to-book (P/B) of 2.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Chongqing Taiji Industry(Group)?
Chongqing Taiji Industry(Group) runs a net profit margin of 1.1%, a gross margin of 30.6%, and an operating margin of 2.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Chongqing Taiji Industry(Group) generate?
Chongqing Taiji Industry(Group) reported revenue of ¥10.4B for fiscal year 2025, with net income of ¥121M and earnings per share (EPS) of 0.22. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Chongqing Taiji Industry(Group) pay a dividend?
Chongqing Taiji Industry(Group) does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Chongqing Taiji Industry(Group) financially healthy?
Chongqing Taiji Industry(Group) carries a debt-to-equity ratio of 1.80x and a current ratio of 0.74x, with a market beta of 0.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Chongqing Taiji Industry(Group) a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Chongqing Taiji Industry(Group) (600129) the key facts are: market cap ¥8.8B, P/E 77.0x, revenue ¥10.4B, 52-week range 11.56-25.51. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Chongqing Taiji Industry(Group)'s full fundamentals live
Get Chongqing Taiji Industry(Group)'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.